Titre : Porphyrines

Porphyrines : Questions médicales fréquentes

Termes MeSH sélectionnés :

Visual Fields
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Porphyrines : Questions médicales les plus fréquentes", "headline": "Porphyrines : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Porphyrines : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-03-04", "dateModified": "2025-02-27", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Porphyrines" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Pigments biologiques", "url": "https://questionsmedicales.fr/mesh/D010860", "about": { "@type": "MedicalCondition", "name": "Pigments biologiques", "code": { "@type": "MedicalCode", "code": "D010860", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.767" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Coproporphyrines", "alternateName": "Coproporphyrins", "url": "https://questionsmedicales.fr/mesh/D003306", "about": { "@type": "MedicalCondition", "name": "Coproporphyrines", "code": { "@type": "MedicalCode", "code": "D003306", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.767.727.250" } } }, { "@type": "MedicalWebPage", "name": "Deutéroporphyrines", "alternateName": "Deuteroporphyrins", "url": "https://questionsmedicales.fr/mesh/D003905", "about": { "@type": "MedicalCondition", "name": "Deutéroporphyrines", "code": { "@type": "MedicalCode", "code": "D003905", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.767.727.280" } } }, { "@type": "MedicalWebPage", "name": "Étioporphyrines", "alternateName": "Etioporphyrins", "url": "https://questionsmedicales.fr/mesh/D005044", "about": { "@type": "MedicalCondition", "name": "Étioporphyrines", "code": { "@type": "MedicalCode", "code": "D005044", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.767.727.340" } } }, { "@type": "MedicalWebPage", "name": "Hématoporphyrines", "alternateName": "Hematoporphyrins", "url": "https://questionsmedicales.fr/mesh/D006415", "about": { "@type": "MedicalCondition", "name": "Hématoporphyrines", "code": { "@type": "MedicalCode", "code": "D006415", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.767.727.462" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Hématoporphyrine D", "alternateName": "Hematoporphyrin Derivative", "url": "https://questionsmedicales.fr/mesh/D017324", "about": { "@type": "MedicalCondition", "name": "Hématoporphyrine D", "code": { "@type": "MedicalCode", "code": "D017324", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.767.727.462.400" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Éther de dihématoporphyrine", "alternateName": "Dihematoporphyrin Ether", "url": "https://questionsmedicales.fr/mesh/D017323", "about": { "@type": "MedicalCondition", "name": "Éther de dihématoporphyrine", "code": { "@type": "MedicalCode", "code": "D017323", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.767.727.462.400.200" } } } ] }, { "@type": "MedicalWebPage", "name": "Éther de dihématoporphyrine", "alternateName": "Dihematoporphyrin Ether", "url": "https://questionsmedicales.fr/mesh/D017323", "about": { "@type": "MedicalCondition", "name": "Éther de dihématoporphyrine", "code": { "@type": "MedicalCode", "code": "D017323", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.767.727.462.400.200" } } } ] }, { "@type": "MedicalWebPage", "name": "Mésoporphyrines", "alternateName": "Mesoporphyrins", "url": "https://questionsmedicales.fr/mesh/D008652", "about": { "@type": "MedicalCondition", "name": "Mésoporphyrines", "code": { "@type": "MedicalCode", "code": "D008652", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.767.727.620" } } }, { "@type": "MedicalWebPage", "name": "Métalloporphyrines", "alternateName": "Metalloporphyrins", "url": "https://questionsmedicales.fr/mesh/D008665", "about": { "@type": "MedicalCondition", "name": "Métalloporphyrines", "code": { "@type": "MedicalCode", "code": "D008665", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.767.727.640" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Hème", "alternateName": "Heme", "url": "https://questionsmedicales.fr/mesh/D006418", "about": { "@type": "MedicalCondition", "name": "Hème", "code": { "@type": "MedicalCode", "code": "D006418", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.767.727.640.587" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Hémine", "alternateName": "Hemin", "url": "https://questionsmedicales.fr/mesh/D006427", "about": { "@type": "MedicalCondition", "name": "Hémine", "code": { "@type": "MedicalCode", "code": "D006427", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.767.727.640.587.462" } } } ] }, { "@type": "MedicalWebPage", "name": "Hémine", "alternateName": "Hemin", "url": "https://questionsmedicales.fr/mesh/D006427", "about": { "@type": "MedicalCondition", "name": "Hémine", "code": { "@type": "MedicalCode", "code": "D006427", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.767.727.640.587.462" } } } ] }, { "@type": "MedicalWebPage", "name": "Protoporphyrines", "alternateName": "Protoporphyrins", "url": "https://questionsmedicales.fr/mesh/D011524", "about": { "@type": "MedicalCondition", "name": "Protoporphyrines", "code": { "@type": "MedicalCode", "code": "D011524", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.767.727.725" } } }, { "@type": "MedicalWebPage", "name": "Uroporphyrines", "alternateName": "Uroporphyrins", "url": "https://questionsmedicales.fr/mesh/D014578", "about": { "@type": "MedicalCondition", "name": "Uroporphyrines", "code": { "@type": "MedicalCode", "code": "D014578", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.767.727.880" } } } ], "about": { "@type": "MedicalCondition", "name": "Porphyrines", "alternateName": "Porphyrins", "code": { "@type": "MedicalCode", "code": "D011166", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Harry L Anderson", "url": "https://questionsmedicales.fr/author/Harry%20L%20Anderson", "affiliation": { "@type": "Organization", "name": "Department of Chemistry, University of Oxford, Chemistry Research Laboratory, OX1 3TA, Oxford, UK." } }, { "@type": "Person", "name": "Donato Monti", "url": "https://questionsmedicales.fr/author/Donato%20Monti", "affiliation": { "@type": "Organization", "name": "Department of Chemistry, Sapienza, University of Rome Piazzale Aldo Moro 5 00185 Rome Italy." } }, { "@type": "Person", "name": "Manuela Stefanelli", "url": "https://questionsmedicales.fr/author/Manuela%20Stefanelli", "affiliation": { "@type": "Organization", "name": "Department of Chemical Science and Technologies, University of Rome Tor Vergata via della Ricerca Scientifica 1 00133 Rome Italy gabriele.magna@uniroma2.it." } }, { "@type": "Person", "name": "Gabriele Magna", "url": "https://questionsmedicales.fr/author/Gabriele%20Magna", "affiliation": { "@type": "Organization", "name": "Department of Chemical Science and Technologies, University of Rome Tor Vergata via della Ricerca Scientifica 1 00133 Rome Italy gabriele.magna@uniroma2.it." } }, { "@type": "Person", "name": "Roberto Paolesse", "url": "https://questionsmedicales.fr/author/Roberto%20Paolesse", "affiliation": { "@type": "Organization", "name": "Department of Chemical Science and Technologies, University of Rome Tor Vergata via della Ricerca Scientifica 1 00133 Rome Italy gabriele.magna@uniroma2.it." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Humphrey visual field made easy for residents.", "datePublished": "2024-09-27", "url": "https://questionsmedicales.fr/article/39331457", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.4103/IJO.IJO_2519_23" } }, { "@type": "ScholarlyArticle", "name": "Detection of post-stroke visual field loss by quantification of the retrogeniculate visual pathway.", "datePublished": "2022-05-27", "url": "https://questionsmedicales.fr/article/35640329", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jns.2022.120297" } }, { "@type": "ScholarlyArticle", "name": "Foveal avascular zone vessel density is associated with visual field progression in early-stage glaucoma eyes with central visual field damage.", "datePublished": "2023-10-25", "url": "https://questionsmedicales.fr/article/37880406", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-023-45541-1" } }, { "@type": "ScholarlyArticle", "name": "Visual feedback in the lower visual field affects postural control during static standing.", "datePublished": "2022-07-08", "url": "https://questionsmedicales.fr/article/35843008", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.gaitpost.2022.07.004" } }, { "@type": "ScholarlyArticle", "name": "Five-Year Visual Field Outcomes of the HORIZON Trial.", "datePublished": "2023-02-21", "url": "https://questionsmedicales.fr/article/36813144", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ajo.2023.02.008" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Facteurs biologiques", "item": "https://questionsmedicales.fr/mesh/D001685" }, { "@type": "ListItem", "position": 3, "name": "Pigments biologiques", "item": "https://questionsmedicales.fr/mesh/D010860" }, { "@type": "ListItem", "position": 4, "name": "Porphyrines", "item": "https://questionsmedicales.fr/mesh/D011166" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Porphyrines - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Porphyrines", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-15", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Porphyrines", "description": "Comment diagnostiquer une porphyrie ?\nQuels tests sont utilisés pour les porphyrines ?\nQuels symptômes indiquent une porphyrie ?\nLes tests génétiques sont-ils nécessaires ?\nComment interpréter les résultats des tests ?", "url": "https://questionsmedicales.fr/mesh/D011166?mesh_terms=Visual+Fields&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Porphyrines", "description": "Quels sont les symptômes courants des porphyries ?\nLes porphyries causent-elles des douleurs ?\nY a-t-il des symptômes cutanés ?\nLes porphyries affectent-elles le système nerveux ?\nLes symptômes varient-ils selon le type de porphyrie ?", "url": "https://questionsmedicales.fr/mesh/D011166?mesh_terms=Visual+Fields&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Porphyrines", "description": "Comment prévenir les crises de porphyrie ?\nY a-t-il des conseils diététiques pour les patients ?\nLes patients doivent-ils éviter certains médicaments ?\nLa gestion du stress est-elle importante ?\nLes patients doivent-ils être suivis régulièrement ?", "url": "https://questionsmedicales.fr/mesh/D011166?mesh_terms=Visual+Fields&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Porphyrines", "description": "Quel est le traitement principal des porphyries ?\nLes transfusions sanguines sont-elles nécessaires ?\nY a-t-il des médicaments spécifiques pour les porphyries ?\nComment gérer les crises de porphyrie ?\nLa photoprotection est-elle recommandée ?", "url": "https://questionsmedicales.fr/mesh/D011166?mesh_terms=Visual+Fields&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Porphyrines", "description": "Quelles sont les complications possibles des porphyries ?\nLes porphyries peuvent-elles causer des dommages au foie ?\nY a-t-il un risque accru de cancer ?\nLes complications neurologiques sont-elles fréquentes ?\nComment gérer les complications des porphyries ?", "url": "https://questionsmedicales.fr/mesh/D011166?mesh_terms=Visual+Fields&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Porphyrines", "description": "Quels sont les facteurs de risque des porphyries ?\nL'hérédité joue-t-elle un rôle ?\nLes femmes sont-elles plus à risque ?\nL'alcool augmente-t-il le risque ?\nLes infections peuvent-elles aggraver la condition ?", "url": "https://questionsmedicales.fr/mesh/D011166?mesh_terms=Visual+Fields&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une porphyrie ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des tests sanguins et urinaires pour mesurer les niveaux de porphyrines." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour les porphyrines ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests incluent l'analyse des urines, du sang et parfois des biopsies de peau." } }, { "@type": "Question", "name": "Quels symptômes indiquent une porphyrie ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent inclure des douleurs abdominales, des troubles neurologiques et des photosensibilités." } }, { "@type": "Question", "name": "Les tests génétiques sont-ils nécessaires ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des tests génétiques peuvent aider à confirmer certains types de porphyries héréditaires." } }, { "@type": "Question", "name": "Comment interpréter les résultats des tests ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux élevés de porphyrines dans le sang ou l'urine indiquent une porphyrie." } }, { "@type": "Question", "name": "Quels sont les symptômes courants des porphyries ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des douleurs abdominales, des éruptions cutanées et des troubles mentaux." } }, { "@type": "Question", "name": "Les porphyries causent-elles des douleurs ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des douleurs abdominales aiguës sont fréquentes lors des crises de porphyrie." } }, { "@type": "Question", "name": "Y a-t-il des symptômes cutanés ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des éruptions cutanées et une photosensibilité peuvent survenir, surtout dans la porphyrie cutanée." } }, { "@type": "Question", "name": "Les porphyries affectent-elles le système nerveux ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent provoquer des troubles neurologiques, y compris des crises et des hallucinations." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon le type de porphyrie ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, chaque type de porphyrie présente des symptômes spécifiques et des manifestations cliniques." } }, { "@type": "Question", "name": "Comment prévenir les crises de porphyrie ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Éviter les déclencheurs comme certains médicaments, l'alcool et le stress peut aider." } }, { "@type": "Question", "name": "Y a-t-il des conseils diététiques pour les patients ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée et riche en glucides peut aider à prévenir les crises." } }, { "@type": "Question", "name": "Les patients doivent-ils éviter certains médicaments ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains médicaments peuvent déclencher des crises et doivent être évités." } }, { "@type": "Question", "name": "La gestion du stress est-elle importante ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la gestion du stress est cruciale pour prévenir les crises de porphyrie." } }, { "@type": "Question", "name": "Les patients doivent-ils être suivis régulièrement ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un suivi médical régulier est essentiel pour surveiller l'évolution de la maladie." } }, { "@type": "Question", "name": "Quel est le traitement principal des porphyries ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement principal inclut l'évitement des déclencheurs et des médicaments pour soulager les symptômes." } }, { "@type": "Question", "name": "Les transfusions sanguines sont-elles nécessaires ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Dans certains cas, des transfusions peuvent être nécessaires pour traiter l'anémie associée." } }, { "@type": "Question", "name": "Y a-t-il des médicaments spécifiques pour les porphyries ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments comme l'hématine peuvent être utilisés pour traiter les crises aiguës de porphyrie." } }, { "@type": "Question", "name": "Comment gérer les crises de porphyrie ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Les crises peuvent être gérées par des soins d'urgence et des traitements symptomatiques." } }, { "@type": "Question", "name": "La photoprotection est-elle recommandée ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les patients doivent éviter l'exposition au soleil et utiliser des écrans solaires." } }, { "@type": "Question", "name": "Quelles sont les complications possibles des porphyries ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des lésions nerveuses, des problèmes hépatiques et des infections." } }, { "@type": "Question", "name": "Les porphyries peuvent-elles causer des dommages au foie ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines porphyries peuvent entraîner des lésions hépatiques graves." } }, { "@type": "Question", "name": "Y a-t-il un risque accru de cancer ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Certaines porphyries, comme la porphyrie cutanée, peuvent augmenter le risque de cancer de la peau." } }, { "@type": "Question", "name": "Les complications neurologiques sont-elles fréquentes ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des complications neurologiques peuvent survenir, affectant la qualité de vie." } }, { "@type": "Question", "name": "Comment gérer les complications des porphyries ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "La gestion des complications nécessite un suivi médical et des traitements adaptés." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque des porphyries ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des antécédents familiaux, certains médicaments et des conditions hépatiques." } }, { "@type": "Question", "name": "L'hérédité joue-t-elle un rôle ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines porphyries sont héréditaires et peuvent être transmises dans les familles." } }, { "@type": "Question", "name": "Les femmes sont-elles plus à risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Certaines études montrent que les femmes peuvent être plus touchées par certaines porphyries." } }, { "@type": "Question", "name": "L'alcool augmente-t-il le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la consommation d'alcool peut déclencher des crises chez les personnes prédisposées." } }, { "@type": "Question", "name": "Les infections peuvent-elles aggraver la condition ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines infections peuvent exacerber les symptômes des porphyries." } } ] } ] }

Sources (10000 au total)

Humphrey visual field made easy for residents.

Visual field testing is an indispensable part of the assessment of glaucoma. Of paramount importance to both the practitioner and the perimetrist is the guidance on how to conduct the test to get the ... To simplify the basics of understanding single-field analysis of visual field tests by using the Humphrey perimeter.... The general principle and a brief overview of how the Humphrey visual field is conducted and the approach to interpreting the results of single field analysis in an easy-to-understand manner are prese... This educational video is an attempt to simplify the interpretation of Humphrey visual field single-field analysis with illustrations and video clips that would be useful to practicing ophthalmologist... https://youtu.be/x8iZLDR4XdY....

Foveal avascular zone vessel density is associated with visual field progression in early-stage glaucoma eyes with central visual field damage.

We investigated the relationship between foveal avascular zone (FAZ)-related parameters, assessed by optical coherence tomography angiography (OCT-A), and visual field (VF) progression in early-stage ...

Visual feedback in the lower visual field affects postural control during static standing.

The dorsal parietal visual system plays an important role in self-motion perception and spatial cognition. It also strongly responds to visual inputs from the lower visual field. Postural control is m... Do visual stimuli presented to the lower and upper visual fields affect postural control and sensory reweighting?... Twenty-nine healthy young adults participated in the study. Four conditions (full visual field, upper visual field, lower visual field, and no optic flow condition) were simulated in a VR environment ... Optic flow in the full and lower visual fields produced significantly smaller 95 % ellipse area and RMS of COP in the anterior-posterior direction compared to optic flow in the upper visual field. Furth... Visual feedback affects static postural control more when presented in the lower visual field compared to the upper visual field....

Five-Year Visual Field Outcomes of the HORIZON Trial.

To compare visual field (VF) progression between glaucoma patients receiving cataract surgery alone (CS) or with a Hydrus microstent (CS-HMS).... Post hoc analysis of VF data from the HORIZON multicenter randomized controlled trial.... A total of 556 patients with glaucoma and cataract were randomized 2:1 to either CS-HMS (369) or CS (187) and followed up for 5 years. VF was performed at 6 months and then every year after surgery. W... Data from 352 eyes in the CS-HMS arm and 165 in the CS arm were analyzed (2966 VFs). The mean RoP was -0.26 dB/y (95% credible interval -0.36, -0.16) for CS-HMS and -0.49 dB/y (95% credible interval -... CS-HMS has a significant effect on VF preservation in glaucoma patients compared with CS alone, reducing the proportion of fast progressors....

Effect of trabeculectomy on the rate of progression of visual field damage.

This study quantifies the effect of trabeculectomy on the rate of progression (RoP) of visual field (VF) damage utilising pre- and post-operative visual function as the outcome instead of surrogate ou... Clinical and VF data from 199 sequential patients who underwent trabeculectomy between 2015 and 2016 were extracted from the network of sites of Moorfields Eye Hospital NHS Foundation Trust. Of these,... We analysed 10 [9,12] VFs per subject (Median [Interquartile Range]). At surgery, the age was 67 [57, 72] years, mean deviation was -10.84 [-14.7, -5.6] dB and the IOP was 18 [15, 20] mmHg. One year a... Trabeculectomy leads to a significant reduction in the RoP of VF loss postoperatively....

A Consensus Statement on the Terminology for Automated Visual Field Abnormalities.

A multitude of terms have been used to describe automated visual field abnormalities. To date, there is no universally accepted system of definitions or guidelines. Variability among clinicians create... In phase one of the study, all neuro-ophthalmologists in Israel were asked to complete a survey in which they described the abnormalities in 10 selected automated visual field tests. In phase 2 of the... Twenty-six neuro-ophthalmologists participated in the initial survey. On average, there were 7.5 unique descriptions for each of the visual fields (SD 3.17), a description of only the location in 24.6... The study confirmed a great degree of variability in the use of terminology to describe automated visual field abnormalities. The creation of a consensus statement was associated with improved use of ...

Gaze tracker parameters have little association with visual field metrics of intrasession frontloaded SITA-Faster 24-2 visual field results.

To determine the usefulness of Humphrey Field Analyser (HFA) SITA-Faster 24-2 gaze tracker outputs on interpreting intra-visit visual field (VF) result pairs.... Analysis of 1380 right-left eye pairs and 1432 pairs of test 1-test 2 intrasession VF results of patients seen within a university-based glaucoma service was undertaken to understand gaze deviation di... There was no association of test order (right-left, test 1-test 2) with eye movements. There was a significant, but weak correlation between eye movements and age (r = 0.16). Correlations of eye movem... Eye movement parameters as currently reported by the HFA do not appear to be correlated with key sensitivity parameters when considering the repeatability of intrasession SITA-Faster 24-2 VF results. ...

Peripheral visual field loss and activities of daily living.

Peripheral visual field (VF) loss affects 13% of the population over 65. Its effect on activities of daily living and higher order visual processing is as important as it is inadequately understood. T... In this review, glaucoma and retrochiasmal cortical damage are utilized as examples of peripheral field loss which typically spare central vision and have patterns respecting the horizontal and vertic... Peripheral VF loss is an under-recognized cause of patient distress and disability. All peripheral field loss is not the same, differential patterns of loss affect parameters of activities of daily li...